283 related articles for article (PubMed ID: 24947909)
21. Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual.
Lopes G; Quesada J; Ahn E; Flores A; Ribeiro A; Rocha-Lima CM
Clin Colorectal Cancer; 2007 Sep; 6(9):641-5. PubMed ID: 17945036
[TBL] [Abstract][Full Text] [Related]
22. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.
Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL
Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025
[TBL] [Abstract][Full Text] [Related]
23. Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.
Lee DJ; Lee J; Lee HY; Lim T; Lee SJ; Yi SY; Park SH; Park JO; Lim HY; Kang WK; Park YS
Med Oncol; 2011 Dec; 28 Suppl 1():S291-4. PubMed ID: 21116875
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U
Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625
[TBL] [Abstract][Full Text] [Related]
25. S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Kim SY; S Hong Y; K Shim E; Kong SY; Shin A; Baek JY; Jung KH
Br J Cancer; 2013 Sep; 109(6):1420-7. PubMed ID: 23963147
[TBL] [Abstract][Full Text] [Related]
26. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
28. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
Delord JP; Bennouna J; Artru P; Perrier H; Husseini F; Desseigne F; François E; Faroux R; Smith D; Piedbois P; Naman H; Douillard JY; Bugat R
Br J Cancer; 2007 Aug; 97(3):297-301. PubMed ID: 17637682
[TBL] [Abstract][Full Text] [Related]
31. Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
Ziras N; Potamianou A; Varthalitis I; Syrigos K; Tsousis S; Boukovinas I; Tselepatiotis E; Christofillakis C; Georgoulias V
Oncology; 2006; 70(2):106-14. PubMed ID: 16645323
[TBL] [Abstract][Full Text] [Related]
32. Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.
Baek JH; Kim H; Ahn JJ; Jegal Y; Seo KW; Ra SW; Park CR; Jung JP; Kim JW; Lee YJ; Cha HJ; Kwon WJ; Noh YJ; Oh S; Park JH; Min YJ
Lung Cancer; 2012 Jun; 76(3):368-72. PubMed ID: 22192919
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
Kim SY; Hong YS; Kim BC; Park JW; Choi HS; Jeong SY; Kim DY; Hong CW; Sohn DK; Jung KH
Invest New Drugs; 2009 Jun; 27(3):269-74. PubMed ID: 18815728
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
Okabayashi K; Hasegawa H; Ishii Y; Endo T; Ochiai H; Kubota T; Kitagawa Y
Cancer Chemother Pharmacol; 2009 Feb; 63(3):501-7. PubMed ID: 18461329
[TBL] [Abstract][Full Text] [Related]
35. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
36. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Souglakos J; Kalykaki A; Vamvakas L; Androulakis N; Kalbakis K; Agelaki S; Vardakis N; Tzardi M; Kotsakis AP; Gioulbasanis J; Tsetis D; Sfakiotaki G; Chatzidaki D; Mavroudis D; Georgoulias V
Ann Oncol; 2007 Feb; 18(2):305-10. PubMed ID: 17079693
[TBL] [Abstract][Full Text] [Related]
38. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Hong YS; Kim HJ; Park SJ; Kim KP; Lee JL; Park JH; Kim JH; Lim SB; Yu CS; Kim JC; Baek JY; Kim SY; Kim TW
Cancer Sci; 2013 Apr; 104(4):473-80. PubMed ID: 23298313
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Jordan K; Kellner O; Kegel T; Schmoll HJ; Grothey A
Clin Colorectal Cancer; 2004 May; 4(1):46-50. PubMed ID: 15207020
[TBL] [Abstract][Full Text] [Related]
40. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
